RNA-protein granules comprising fusion proteins and RNA are disclosed, as well as uses thereof for treating or preventing viral infection. Soluble fusion proteins comprising an extracellular domain of a human receptor or a fragment thereof and a bacteriophage coat protein, as well as synthetic microcarriers comprising a solid support conjugated to a plurality of viral proteins or fragments thereof are provided. Nucleic acid molecules and vectors encoding the soluble fusion protein, synthetic RNA-protein granules comprising a fusion protein, as well as method using the soluble fusion protein are also provided.

A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.